SNCA-targeted epigenome therapy for Parkinsons disease alleviates pathological and behavioral perturbations in a mouse model
Bernadette O’Donovan, Joseph E. Rittiner, Suraj Upadhya, Dellila Hodgson, Boris Kantor, Ornit Chiba‐Falek
This study demonstrates that SNCA-targeted epigenome therapy reduces α-synuclein expression, aggregation, and motor deficits in a PD mouse model.
bioRxiv · Jun 16, 2025 · PreprintNeuroscience